Theravance Biopharma, Inc. financial data

Symbol
TBPH on Nasdaq
Location
Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 561 % -1.43%
Return On Equity 6.93 %
Return On Assets 3.52 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50.4M shares +2.94%
Common Stock, Shares, Outstanding 50.4M shares +2.94%
Entity Public Float 335M USD -27%
Common Stock, Value, Issued 1K USD
Weighted Average Number of Shares Outstanding, Basic 50.2M shares +2.93%
Weighted Average Number of Shares Outstanding, Diluted 50.7M shares +4.06%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 77.2M USD +24.5%
Research and Development Expense 40.7M USD +14.4%
Operating Income (Loss) -37.2M USD +11.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 40.1M USD
Income Tax Expense (Benefit) 27M USD +264%
Net Income (Loss) Attributable to Parent 13M USD
Earnings Per Share, Basic 0 USD/shares
Earnings Per Share, Diluted 0 USD/shares

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 282M USD +508%
Assets, Current 366M USD +207%
Property, Plant and Equipment, Net 6.64M USD -18.4%
Operating Lease, Right-of-Use Asset 26.5M USD -16.7%
Other Assets, Noncurrent 25.8M USD +233%
Assets 426M USD +17.7%
Accounts Payable, Current 1.68M USD +0.06%
Employee-related Liabilities, Current 7.26M USD +25.7%
Contract with Customer, Liability, Current 24K USD 0%
Liabilities, Current 54.6M USD +138%
Contract with Customer, Liability, Noncurrent 175K USD -12.1%
Operating Lease, Liability, Noncurrent 35.6M USD -16.2%
Other Liabilities, Noncurrent 1.55M USD -68.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax -10K USD +54.5%
Retained Earnings (Accumulated Deficit) -924M USD +1.39%
Stockholders' Equity Attributable to Parent 225M USD +16.1%
Liabilities and Equity 426M USD +17.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 43M USD
Net Cash Provided by (Used in) Financing Activities -854K USD +50.2%
Net Cash Provided by (Used in) Investing Activities 30.6M USD +79.9%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 50.4M shares +2.94%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 72.8M USD +410%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 283M USD +499%
Deferred Tax Assets, Valuation Allowance 436M USD +1.32%
Deferred Tax Assets, Gross 452M USD +0.96%
Operating Lease, Liability 49.8M USD +1.35%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 13M USD
Lessee, Operating Lease, Liability, to be Paid 62.9M USD -4.84%
Property, Plant and Equipment, Gross 29.8M USD -2.71%
Operating Lease, Liability, Current 10.9M USD +158%
Lessee, Operating Lease, Liability, to be Paid, Year Two 11.4M USD +4.33%
Lessee, Operating Lease, Liability, to be Paid, Year One 11.2M USD +188%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Deferred Income Tax Expense (Benefit) -1.85M USD -261%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 13.1M USD +29.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 11.7M USD +4.32%
Deferred Tax Assets, Operating Loss Carryforwards 154M USD +0.82%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 230K shares 0%
Unrecognized Tax Benefits 83.7M USD +5.27%
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.7M USD +2.27%
Additional Paid in Capital 1.15B USD +1.6%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 16M USD -8.03%
Share-based Payment Arrangement, Expense 20.2M USD -10.9%
Interest Expense 2.43M USD -49.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%